// App-Quantinova.ai

9569 : Analysis of patients (pts) with in-transit metastases treated with nivolumab (NIVO) or ipilimumab (IPI) in CheckMate 238.

Researchers

Presenter

  • James Larkin

Principal Investigators

  • Michele Del Vecchio

  • Michele Maio

  • Petr Arenberger

  • Ana Maria Arance

  • Jean-Jacques Grob

  • Vanna Chiarion-Sileni

  • Karl D. Lewis

  • Laurent Mortier

  • Patrick Alexander Ott

  • Georgina V. Long

  • Alfonsus Van Den Eertwegh

  • C. Lance Cowey

  • Michael Schenker

  • Marcus O. Butler

  • Maurice Lobo

  • Margarita Askelson

  • Paolo Antonio Ascierto

  • Jeffrey S. Weber

Medical Centers

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • National and Kapodistrian University of Athens, Athens, Greece

  • Head, Unit of Melanoma Medical Oncology Department of Medical Oncology and Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy

  • Center for Immuno-Oncology, University Hospital of Siena, Siena, Italy

  • Department of Dermatology, Charles University Third Faculty of Medicine and University Hospital Kralovske Vinohrady, Prague, Czech Republic, Department of Medical Oncology, Hospital Clinic Barcelona, Barcelona, Spain

  • Aix-Marseille University, Hopital de la Timone, Marseille, France

  • Head of Melanoma Cancer Unit, Melanoma Oncology Unit, Veneto Institute of Oncology IOV–IRCCS, Padua, Italy

  • University of Colorado Cancer Center, Aurora, CO

  • Universite Lille, Centre Hospitalier Regional Universitaire de Lille, Lille, France

  • Dana-Farber Cancer Institute, Boston, MA

  • Professor of Melanoma Medical Oncology and Translational Research, Melanoma Institute Australia

  • University of Sydney and Royal North Shore and Mater Hospitals, Sydney, Australia

  • Amsterdam University Medical Center - Amsterdam - Netherlands (The)

  • Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas, TX

  • Oncology Center of Sf Nectarie Ltd., Craiova, Romania

  • Tumor Immunotherapy Program, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Toronto, ON, Canada

  • Canada.

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Biostatistics, Bristol Myers Squibb, Princeton, NJ

  • Istituto Nazionale Tumori Fondazione G. Pascale, Naples, Italy

  • Laura and Isaac Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY

Locations

  • United Kingdom

  • Greece

  • Italy

  • Spain

  • France

  • United States

  • Australia

  • Netherlands

  • Romania

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Melanoma

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Ipilimumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • III

Study Id's

  • NCT02388906

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved